These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19410277)

  • 1. Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia.
    Elalamy I; Tardy-Poncet B; Mulot A; de Maistre E; Pouplard C; Nguyen P; Cleret B; Gruel Y; Lecompte T; Tardy B;
    Thromb Res; 2009 Nov; 124(5):554-9. PubMed ID: 19410277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
    Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
    Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
    Magnani HN; Gallus A
    Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of heparin-induced thrombocytopenia.
    Keeling D; Davidson S; Watson H;
    Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multidisciplinary consultation for the prescription of danaparoid in suspected heparin-induced thrombocytopenia].
    Verdy E; Debrix I; Benomar A; Becker A; Flahault A
    Presse Med; 2007 May; 36(5 Pt 1):786-93. PubMed ID: 17303370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
    Lubenow N; Warkentin TE; Greinacher A; Wessel A; Sloane DA; Krahn EL; Magnani HN
    Thromb Res; 2006; 117(5):507-15. PubMed ID: 15907979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
    Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Müller MM; Kropff S; Lindhoff-Last E
    J Am Coll Cardiol; 2017 Nov; 70(21):2636-2648. PubMed ID: 29169470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients.
    Wester JP; Haas FJ; Biesma DH; Leusink JA; Veth G
    Intensive Care Med; 2004 Oct; 30(10):1927-34. PubMed ID: 15156309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management.
    Napolitano LM; Warkentin TE; Almahameed A; Nasraway SA
    Crit Care Med; 2006 Dec; 34(12):2898-911. PubMed ID: 17075368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
    Kodityal S; Manhas AH; Udden M; Rice L
    Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin-induced thrombocytopenia in intensive care patients.
    Selleng K; Warkentin TE; Greinacher A
    Crit Care Med; 2007 Apr; 35(4):1165-76. PubMed ID: 17334253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment options for heparin-induced thrombocytopenia.
    Ortel TL; Chong BH
    Semin Hematol; 1998 Oct; 35(4 Suppl 5):26-34; discussion 35-6. PubMed ID: 9855181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report.
    Horlait G; Minet V; Mullier F; Michaux I
    Blood Coagul Fibrinolysis; 2017 Mar; 28(2):193-197. PubMed ID: 27100305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
    Ibbotson T; Perry CM
    Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current agents for the treatment of patients with heparin-induced thrombocytopenia.
    Warkentin TE
    Curr Opin Pulm Med; 2002 Sep; 8(5):405-12. PubMed ID: 12172444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases.
    Tardy-Poncet B; Wolf M; Lasne D; Bauters A; Ffrench P; Elalamy I; Tardy B
    Intensive Care Med; 2009 Aug; 35(8):1449-53. PubMed ID: 19350215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of 51 pregnancies with danaparoid because of heparin intolerance.
    Lindhoff-Last E; Kreutzenbeck HJ; Magnani HN
    Thromb Haemost; 2005 Jan; 93(1):63-9. PubMed ID: 15630492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Heparin-induced thrombocytopenia].
    Christoffersen C; Lethagen S; Gøtze JP
    Ugeskr Laeger; 2009 Feb; 171(8):612-5. PubMed ID: 19284907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases].
    Schindewolf M; Magnani HN; Lindhoff-Last E
    Hamostaseologie; 2007 May; 27(2):89-97. PubMed ID: 17479171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.